Hostname: page-component-8448b6f56d-tj2md Total loading time: 0 Render date: 2024-04-25T04:28:31.669Z Has data issue: false hasContentIssue false
  • English
  • Français

Biological variables in predicting the outcome of psychological treatment in schizophrenia

Published online by Cambridge University Press:  11 October 2011

A. Carlo Altamura ,
Caterina Burrai  and
Riccardo Curreli
Rights & Permissions [Opens in a new window]

Abstract

An abstract is not available for this content so a preview has been provided. As you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Editorials
Information
Epidemiology and Psychiatric Sciences , Volume 3 , Issue 3 , December 1994 , pp. 151 - 157
Copyright
Copyright © Cambridge University Press 1994

References

Bibliografia

Aleem, A., Kurlani, A. & Yergani, V.K. (1988). DST, schizophrenia and movement disorders. Ada Psychiatrica Scandinavica 78 689–694.CrossRefGoogle Scholar
Altamura, A.C. (1992). A multidimensional (pharmacokinetic and clinical-biological) approach to neuroleptic response in schizophrenia (with particular reference to drug resistance). Schizophrenia Research 8, 187–198.CrossRefGoogle Scholar
Altamura, A.C, Cavallaro, R. & Mauri, M.C. (1989). Hydroxy HL and clinical outcome in schizophrenia. In Clinical Pharmacology in Psychiatry (ed. Dahal, S.G. and Gram, L.F.), pp. 263–268. Springer-Verlag: Berlin-Heidelberg.CrossRefGoogle Scholar
Altamura, A.C, Guercetti, G. & Percudani, M. (1989). DST in positive and negative schizophrenia. Psychiatry Research 30, 69–75.CrossRefGoogle Scholar
Bacopoulos, N.G., Spokes, E.G., Bird, E.D. & Roth, R.H. (1979) Antipsychotic action in schizophrenic patients: effects on cortical dopamine metabolism after long-term treatment. Science 205, 1405–1407.CrossRefGoogle ScholarPubMed
Beasley, C.M., Magnusson, M. & Garver, D.L. (1987). TSH response to TRH and haloperidol response in psychoses. Biological Psychiatry 24, 423–431.CrossRefGoogle Scholar
Bowers, M.B. (1974). Central dopamine turnover in schizophrenic syndrome. Archives of General Psychiatry 31, 50–54.CrossRefGoogle Scholar
Bowers, M.B., Swigar, M.E., Jatlow, P.L., Hoffman, F. & Gocoechea, N. (1986). Early neuroleptics response in psycotic men and women: correlation with plasma HVA and MHPG. Comprehensive Psychiatry 27, 181–185.CrossRefGoogle Scholar
Bowers, M.B., Swigar, M.E., Jatlow, P.I., Hofmann, F. & Giocoechea, N. (1987). Early neuroleptics response: clinical profile and catecholamine metabolites. Journal of Clinical Psychopharmacology 7, 83–86.CrossRefGoogle ScholarPubMed
Brown, W.A. & Laughren, T.P. (1981). Low serum PRL and early relapse following neuroleptic withdrawal. Archives of General Psychiatry 183, 237–239.Google Scholar
Castro, P., Kemaire, M. & Toscano-Aguilar, M. (1983). Abnormal DST result in patients with chronic schizophrenia. American Journal of Psychiatry 140, 1261.CrossRefGoogle ScholarPubMed
Cazzullo, C.L. & Smeraldi, E. (1979). HLA system, psychiatry and psychopharmacology. Progress in Neuropsychopharmacology 3, 137–146.CrossRefGoogle ScholarPubMed
Cleghorn, J.M., Garnett, E.S., Nahmias, C, Firnau, G. & Brown, J.M. (1989). Increased frontal and reduced parietal glucose metabolism in acute untreated schizophrenia. Psychiatry Research 28, 119–133.CrossRefGoogle ScholarPubMed
Coppen, A., Abon-Aaleh, M., Milln, P., Metcalfe, M., Harzood, J. & Bailey, J. (1983). DST in depression and other psychiatric illness. British Journal ofPsichiatry 142, 498–504.Google ScholarPubMed
Davidson, M., Keefe, R.S.E. & Mohs, R.C. (1987). L-DOPA challenge and relapse in schizophrenia. Archives of General Psychiatry 144, 934–938.Google ScholarPubMed
Davidson, M., Kahn, R.S., Powchik, P., Waene, P., Losonczy, M.F. & Kaminsky, R. (1991). Changes in pHVA concentrations in schizophrenic patients following neuroleptic discontinuation. Archives of General Psychiatry 48, 73–76.CrossRefGoogle Scholar
Davila, R., Manero, E. & Zumarraga, M. (1988). Plasma HVA as a predictor of neuroleptics. Archives of General Psychiatry 44, 1117–1121.Google Scholar
Davis, J., Janicak, P., Linden, R., Moloney, J. & Pavkovic, I. (1983). Neuroleptics and psychotic disorders. In Neuroleptics: Neurochemical, Behavioural and Clinical Perspectives (ed. Coyle, J.T. and Enna, S.J.), pp. 15–64. Raven Press: New York.Google Scholar
Ereshefski, L. & Davis, C.M. (1984). HL and reduced HL plasma levels in selected schizophrenic patients. Journal of Clinical Psychopharmacology 4, 138–142.Google Scholar
Friedman, L., Knutson, L., Shurall, M. & Meltzer, H.Y. (1991). Prefrontal sulcal prominence is inversely related to response to clozapine in schizophrenia. Biological Psychiatry 29, 865–877.CrossRefGoogle ScholarPubMed
Ganguli, R., Rabin, B.S. & Belle, S.H. (1989). Decreased interleukin-2 production in schizophrenic patients. Biological Psychiatry 26, 424–427.CrossRefGoogle ScholarPubMed
Ganguli, R., Rabin, B.S. & Brar, J.S. (1992). Antinuclear and gastric parietal cell autoantibodies in schizophrenic patients. Biological Psychiatry 32, 735–738.CrossRefGoogle ScholarPubMed
Holsboer-Trachler, E., Buol, C. & Wiederman, K. (1987). DST in severe schizophrenia illness. Ada Psychiatrica Scandinavica 75, 608–613.Google Scholar
Koreen, A.R., Lieberman, J., Alvir, J., Mayerhoff, D., Loebel, A., Chakos, M., Amin, F. & Cooper, T. (1994). Plasma homovanillic acid levels in first-episode schizophrenia. Archives of General Psychiatry 51, 473–483.CrossRefGoogle ScholarPubMed
Langer, G., Koining, G. & Hatzinger, R. (1986). Response to thyrotropin releasing hormone as predictor of outcome. Archives of General Psychiatry 43, 861–868.CrossRefGoogle Scholar
Lieberman, A.J. & Sobel, S. (1993). Predictors of treatment response and course of schizophrenia. Current Opinion in Psychiatry 6, 63–69.CrossRefGoogle Scholar
Lieberman, J., Kane, J., Woerner, M, Alvir, J, Borenstein, M. & Novacenko, H. (1990). Prediction of relapse in schizophrenia. Clinical Neuropharmacology 13, 434–35.Google Scholar
Mauri, M.C., Vita, A., Giobbio, G.M., Ferrara, A., Dieci, M., Bitetto, A. & Atamura, A.C. (1994). Prediction of response to haloperidol in schizophrenia: neuroendocrine, neuromorphological and clinical variables. International Clinical Psychopharmacology 9, 3–7.CrossRefGoogle ScholarPubMed
Mazure, C.M., Nelson, J.C., Jatlov, P.I. & Bowers, M.B. (1991). Plasma free HVA as a predictor of clinical response in acute psychosis. Biological Psychiatry 30, 475–482.CrossRefGoogle ScholarPubMed
McAllister, C.G., Van Kammen, D.P., Rehn, T.J., Miller, A.L., Gurklis, J.A., Kelley, M.E., Yao, J.K. & Peters, J.L. (1994). CSF and plasma interleukin IL-la and 2 in schizophrenia: effects of relapse and medication status. American Journal of Psychiatry (in stampa).Google Scholar
Oucjar, D., Labarca, R., Doran, A.R., Wolkowitz, O.M., Roy, A., Breier, A., Linnoila, M. & Paul, S.M. (1986). Longitudinal measurement of plasma HVA levels in schizophrenic patients. Correlation with psychosis and response to neuroleptic treatment. Archives of General Psychiatry 43, 669–676.Google Scholar
Pickar, D. (1986). Neuroleptics, dopamine and schizophrenia. Psychiatry Clinics of North America 9, 35–48.CrossRefGoogle ScholarPubMed
Pickar, D., Owen, R.R., Litman, R.E., Konicki, P.E., Gutierrez, R. & Rapaport, M.H. (1992). Clinical and biological response to clozapine in patients with schizophrenia: cross-over comparison with fluphenazine. Archives of General Psychiatry 49, 345–353.CrossRefGoogle Scholar
Schlesser, M.A., Winokur, G. & Sherman, B.M. (1980). Hypothalamic pituitary-adrenal axis activity in depressive illness. Archives of General Psychiatry 37, 737–743.CrossRefGoogle ScholarPubMed
Sedvall, G., Alfredsson, G. & Bjerkenstedt, L. (1976). Central biochemical correlates to antipsychotic drug action in man. In The Impact of Biology in Modern Psychiatry (ed. Gershon, E.S. and Belmaker, R.H.), pp. 41–54. Plenum Publishing: New York.Google Scholar
Sharma, R.P., Javaid, J.I., Philip, G., Davis, J.M. & Faull, K. (1993). HVA in the cerebrospinal fluid: patterns of response after four weeks of neuroleptic treatment. Biological Psychiatry 34, 128–134.CrossRefGoogle ScholarPubMed
Smeraldi, E., Bellodi, L. & Scorza, Smeraldi R. (1976). HLA system and schizophrenia: statistical and genetic considerations. Tissue Antigens 8, 191.CrossRefGoogle Scholar
Sternberg, D.E., Van Kammen, D.P., Lerner, P., Ballenger, J.C., Morder, S.R. & Bunney, W.E. (1981). The effect of pimozide on CSF; norepinephrine in schizophrenia. Archives of General Psychiatry 138, 1045–1051.Google ScholarPubMed
Sternberg, D.E., Van Kammen, D.P., Lerner, P. & Bunney, W.E. (1982). Schizophrenia: dopamine beta-hydroxylase activity and treatment response. Science 216, 1423–1425.CrossRefGoogle ScholarPubMed
Sternberg, D.E., Van Kammen, D.P. & Lerner, P. (1983). CSF dopamine beta-hydroxylase in schizophrenia. Archives of General Psychiatry 40, 743–747.CrossRefGoogle ScholarPubMed
Tandon, R., Mazzara, C., De Quardo, J, Craig, C.A., Meador-Woodruf, J.H., Goldman, R. & Greden, F.J. (1991). DST in schizophrenia: relationship to symptomatology, ventricular enlargment and outcome. Biological Psychiatry 29, 953–64.CrossRefGoogle ScholarPubMed
Tandon, R., Taylor, S., Shipley, J.E, Meador-Woodruff, J.H., Ribeiro, S.P. M. & De Quardo, J.R. (1992). Biological predictors of one year outcome in schizophrenia. Biological Psychiatry 31 (suppl.), 84A.Google Scholar
Van Kammen, D.P. (1991). The biochemical basis of relapse and drug response in schizophrenia: review and hypothesis. Psychological Medicine 21, 881–895.CrossRefGoogle ScholarPubMed
Van Kammen, D.P. & Schooler, N. (1990). Are biochemical markers for treatment-resistant schizophrenia state dependent or traits? Clinical Neuropharmacology 13, 16–28.CrossRefGoogle ScholarPubMed
Van Kammen, D.P., McAllister, C.G., Yao, J.K, Kelley, M.E., Gilbertson, M.W., Gurklis, J.A., Inosaka, T. & Peters, J.L. (1994). Interleukin 2 and psychosis predict early relapse in schizophrenia. American Journal of Psychiatry (in stampa).Google Scholar
Van Praag, H.M. & Korf, J. (1975). Neuroleptics, cathecolamines and psychoses: a study of their interrelations. Archives of General Psychiatry 126, 593–597.Google Scholar
Van Putten, T. & Marder, S.R. (1991). Serum PRL as a correlate of clinical response to HL. Journal of Clinical Psychopharmacology 11, 357–361.Google Scholar
Van Putten, T., May, P.R.A. & Marder, S.R. (1984). Response to antipsychotic medication: the doctor's and consumer view. American Journal of Psychiatry 134, 123–131.Google Scholar
Van Putten, T., Marder, S.R., Aravagiri, M., Chabert, N. & Mintz, J. (1989). Plasma HVA as a predictor of response to fluphenazine treatment. Psychopharmacology Bulletin 1, 89–91.Google Scholar
Weinberger, D.R., Bigelow, L.B. & Kleinman, G.E. (1980). Cerebral ventricular enlargement in chronic schizophrenia: association with a poor response to treatment. Archives of General Psychiatry 37, 11–13.CrossRefGoogle ScholarPubMed